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Smoking is highly prevalent in patients with schizophrenia and exerts a negative impact on 
cardiovascular mortality in these patients. Smoking has complex interactions with mono-
amine metabolism through the ability of cigarette smoke to suppress Type 1 T helper cell 
(Th1) type immunity, the immunophenotype that is implicated in phenylalanine hydroxylase 
(PAH) dysfunction and tryptophan (Trp) breakdown to kynurenine (Kyn) via indoleamine 
2,3-dioxygenase. Nicotine also induces tyrosine hydroxylase (TH) gene expression, 
leading to increased synthesis of catecholamines. Furthermore, there is evidence for 
PAH dysfunction in schizophrenia. This study aimed to compare the plasma levels of  
selected monoamine precursors and their metabolites in smokers vs. non-smokers  
in a large sample of patients with schizophrenia. We measured plasma phenylalanine 
(Phe), tyrosine (Tyr), Trp, and Kyn levels using high-performance liquid chromatography 
and calculated Phe:Tyr and Kyn:Trp ratios in 920 patients with schizophrenia. Analysis of 
variance and linear r egression analyses were used to compare these endpoints between 
three groups of patients with schizophrenia: (1) current smokers, (2) past smokers, and 
(3) non-smokers. Ther e were significant differences among the three groups with regards 
to Tyr levels [F(2,789) = 3.77, p = 0.02], with current smokers having lower Tyr levels when 
compared with non-smokers (p = 0.02). Kyn levels and Kyn:Trp ratio were different among 
the three groups [F(2,738) = 3.17, p = 0.04, F(2,738) = 3.61, p = 0.03] with current smokers 
having lower Kyn levels (p = 0.04) and higher Kyn:Trp ratio (p = 0.02) when compared with 
past smokers. These findings need to be replicated with protocols that include healthy 
controls to further elucidate the neurobiological underpinnings of altered Tyr and Kyn lev-
els in smokers. Results do suggest potential molecular links between schizophrenia and 
smoking that may represent biomarkers and treatment targets for reducing an important 
modifiable cause of general morbidity and mortality in patients with schizophrenia.
Keywords: phenylalanine, tyrosine, kynurenine, tryptophan, schizophrenia, smoking
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inTrODUcTiOn
Cigarette smoking is more prevalent in patients with schizophre-
nia in comparison to the general population as well as patients 
with other severe mental illnesses (1). Smoking has recently been 
associated with increased risk of developing schizophrenia (2), 
and it may also represent an expression of general vulnerability 
for substance use disorders in schizophrenia (3). Smoking is also 
an important modifiable risk factor for increased cardiovascular 
morbidity and mortality reported in patients with schizophrenia 
(4, 5). Furthermore, smokers with schizophrenia appear to be at 
an increased risk for suicide (6, 7) when compared with non-
smokers with the illness. Recognizing and addressing smoking 
as a major comorbidity in patients with mental illness, especially 
schizophrenia, is yet to gain impetus in clinical practice (8).
Smoking leads to increased dopaminergic neurotransmission 
(9) and is purported (10) to improve “hypofrontality,” which is 
manifested as negative and cognitive symptoms of schizophrenia 
(11). Cigarette smoke has an inhibitory effect on monoamine 
oxidase, which may also increase the availability of dopamine 
due to its reduced metabolism (12). Impairments in attentional 
processes and other cognitive functions in schizophrenia are 
linked to abnormal sensory gating and dysfunction of alpha-7 
nicotinic cholinergic receptor, which are characterized by a deficit 
in P50 auditory evoked response (10) and prepulse inhibition 
(PPI) (13). Smoking briefly normalizes P50 amplitude in schizo-
phrenia probands and their relatives, and nicotine improves PPI 
and cognition in patients with schizophrenia (14).These findings 
lend evidence to the self-medication hypothesis which suggests 
that increased smoking in schizophrenia may be an attempt to 
compensate for attentional deficits and other symptoms of the 
illness (15).
Smoking may also reduce some side effects of antipsychotic 
medications. For example, polycyclic aromatic hydrocarbons in 
cigarette smoke induce cytP4501A2, which increases metabolism 
of medications (16), thus reducing side effects of these medica-
tions. Increased prevalence of smoking in schizophrenia is also 
proposed to be due to an alleviation of extrapyramidal side effects 
of neuroleptics (17), a finding that is aligned with the evidence for 
a protective effect of smoking in Parkinson’s disease, likely due to 
the ability of nicotine to improve dopaminergic neurotransmis-
sion in the striatum (17). It is therefore possible that patients with 
schizophrenia smoke to alleviate side effects of antipsychotic 
medications.
Phenylalanine (Phe) is an essential amino acid involved in the 
synthesis of dopamine, the neurotransmitter most commonly 
implicated in the pathogenesis of schizophrenia. Phenylalanine 
hydroxylase (PAH) converts Phe to tyrosine (Tyr). Tyr is further 
converted into dopamine via a two-step enzymatic reaction 
involving Tyr hydroxylase (rate-limiting enzymatic reaction 
of catecholamine synthesis) and aromatic l-type amino acid 
decarboxylase (18, 19). Phe:Tyr ratio is considered to be an 
estimate of PAH activity (20). The PAH activity is modulated by 
(6R)-l-erythro-5,6,7,8-tetrahydrobiopterin (BH4), an essential 
cofactor for aromatic amino acid hydroxylases including PAH 
(21). Type 1 T helper (Th1) cell immune activation leads to release 
of pro-inflammatory cytokines and decreased activity of PAH 
despite stimulated BH4 production (22), thus decreasing Phe 
turnover and increasing Phe:Tyr ratio. PAH dysfunction during 
activation of Th1-type immunity is thought to be mediated by 
oxidative stress-induced depletion of BH4 in the context of a 
pro-inflammatory state (20). Moreover, Th1 immune activation 
leads to shunting of tryptophan (Trp) away from serotonin 
synthesis toward kynurenine (Kyn) production via the induction 
of indoleamine 2,3-dioxygenase (IDO) (23) by Th1 cytokines 
like interferon gamma (IFNγ). Kyn:Trp is considered a sensitive 
indicator of IDO activity and Trp degradation; an elevated ratio 
signifying dominant Th1 immune activation (24).
Elevated plasma Phe and reduced Tyr levels seen in patients with 
schizophrenia are presumable consequences of an inflammation-
mediated decrease in PAH activity (25–28). High Phe levels lead 
to increased levels of Phe in the brain, which in turn decreases the 
activity of aromatic amino acid hydroxylases including tyrosine 
hydroxylase (TH) and Trp hydroxylase, thus decreasing overall 
monoamine synthesis in the brain (18). Abnormal Phe kinetics 
was demonstrated in patients with schizophrenia using radiola-
beled Phe breath tests (29). PAH gene polymorphisms have been 
identified in schizophrenia (30, 31).
Cigarette smoking is known to favor Th2 immune responses 
while suppressing Th1 immunity (32). Smoking decreases the 
activity of IDO by inhibiting Th1 responses via suppression of 
IFNγ, a major Th1 cytokine, thereby increasing Trp levels and 
decreasing Kyn:Trp ratio (32) (Figure  1). On the other hand, 
smoking may increase the activity of PAH via carbon monoxide 
(CO)-mediated suppression of IFNγ (22, 33), thus decreasing 
Phe:Tyr ratio.
Alternatively, nicotine reliably increases the expression of TH 
gene, protein, and TH activity both centrally (34) and in adrenal 
medulla (35, 36), possibly leading to decreased Tyr levels. A 
sustained increase in TH activity after a single administration of 
nicotine (37) has been described. Unsurprisingly polymorphisms 
in the TH gene are linked to susceptibility to smoking (38, 39).
The unusually high rate of smoking in patients with schizo-
phrenia and disproportionately high mortality rate from heart 
disease in this population demands scrutiny of the complex 
associations of smoking and schizophrenia. We have previously 
reported that Phe levels and Phe:Tyr ratio were elevated in the 
same cohort of patients with schizophrenia when compared 
with controls (40). To our knowledge, there have been no studies 
investigating links between blood levels of molecular precursors 
of dopamine and serotonin in relationship to smoking in patients 
with schizophrenia.
MaTerials anD MeThODs
The local ethics committee of Ludwig Maximilians University, 
Munich, Germany approved the study, and the additional analysis 
of the data at the University of Maryland, Baltimore, MD, USA 
was determined as exempt by the Institutional Review Board of 
the University of Maryland School of Medicine, Baltimore, MD, 
USA. Written consent was obtained from all study participants 
after detailed description of study procedures. An experienced 
clinical psychiatrist evaluated the participants’ capacity to con-
sent to participate in the study.
FigUre 1 | inflammation, smoking, and monoamine metabolism. Nicotine increases the expression of tyrosine hydroxylase (TH) gene as depicted in 
green (+), thus decreasing tyrosine (Tyr) levels and increasing downstream catecholamine synthesis. Smoking also favors Type 2 helper cell (Th2) immunity over 
Type 1 helper cell (Th1) immunity, in turn, decreasing the activity, depicted in red (−), of indoleamine 2,3-dioxygenase (IDO), consequently maintaining tryptophan 
(Trp) levels and decreasing kynurenine (Kyn). Th2 immune activation favored by smoking also increases the activity of phenylalanine hydroxylase (PAH), depicted in 
green (+). Smoking inhibits monoamine oxidase enzyme, depicted in red (−) and decreases breakdown of serotonin (5-hydroxytryptamine, 5-HT) into 
5-hydroxyindoleacetic acid (5-HIAA). Th1 immunity via interferon gamma (IFNγ) triggers reactive oxygen species (ROS)-induced depletion of tetrahydrobiopterin 
(BH4) leading to PAH dysfunction.
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Participants
Nine hundred and twenty patients with a diagnosis of schizo-
phrenia were enrolled from inpatient and outpatient settings in 
the Munich area in Germany. Structured Clinical Interview for 
DSM-IV TR Axis I Disorders, Research Version, Patient Edition 
(SCID) was used to confirm the diagnosis of schizophrenia 
in patients (41). Subjects who met criteria for schizoaffective 
disorder, schizophreniform disorder, substance-induced psy-
chosis, and psychotic disorder not otherwise specified (NOS) 
were excluded. Positive and negative syndrome scale (PANSS) 
was used to measure severity of symptoms in all patients 
(42). According to their answers on the Fagerstrom Nicotine 
Dependence Test (43), the patients were divided into three 
categories: (1) non-smoker – those who smoked less than 100 
cigarettes in their lifetime (n = 239); (2) past smoker – those who 
smoked more than 100 cigarettes over their lifetime, but no ciga-
rettes in the past week (n = 130); and (3) current smoker – who 
smoked more than 100 cigarettes over their lifetime and any 
amount in the past week (n = 551). Antipsychotic medications 
were recorded, and the chlorpromazine (CPZ) equivalent of 
antipsychotic dosage was calculated.
Measurement of Plasma Phenylalanine, 
Tyrosine, Kynurenine, and Tryptophan
No dietary restrictions or fasting protocols were imposed. 
Blood samples were obtained from a forearm vein and drawn 
in EDTA-containing tubes. After centrifuging the samples 
for 10  min at 4°C, the resulting plasma was aliquoted into 
Eppendorf tubes, which were frozen immediately at −80°C. 
Until analysis, the samples were frozen at −80°C. Using 
high-performance liquid chromatography (HPLC), Phe, Tyr, 
Kyn, and Trp levels were determined by monitoring their 
natural fluorescence as described elsewhere (44, 45). Peak 
height counts were employed to determine concentrations 
TaBle 1 | sample demographic and clinical characteristics.
Variable current smokers (n = 551) Past smokers (n = 130) non-smokers (n = 239) p-Value anOVa
Age, years, mean (SD) 36.6 (11.2) 39.8 (11.8) 40 (11.8) <0.0001
Gender, male, n (%) 389 (70) 75 (57) 120 (50)
BMI mean (SD) 27.1 (5.5) 27 (5.6) 27.1 (5.2) 0.9
CPZ equivalent mean (SD) 542 (1,545) 477 (935) 350 (382) 0.15
PANSS mean (SD)
Positive symptoms mean (SD) 28.2 (6.3) 26.8 (6.5) 26.8 (6.2) 0.004
Negative symptoms mean (SD) 24.7 (6.8) 23.4 (9) 24.1 (7.8) 0.175
General psychopathology mean (SD) 49.3 (11.1) 48.6 (13.6) 49.6 (11.7) 0.729
BMI, body mass index; CPZ equivalent, chlorpromazine equivalent; PANSS, positive and negative syndrome scale.
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after referring Phe, Tyr, Trp, and Kyn to internal standard, 
3-nitro-l-tyrosine.
statistical analysis
The ratio between plasma Phe and Tyr was used to estimate 
the activity of the enzyme PAH (24). Kyn:Trp ratio was used to 
determine the activity of IDO. As the distributions of Phe, Tyr, 
Kyn, Trp, Phe:Tyr, and Kyn:Trp ratio were skewed, we applied 
logarithmic transformation to ensure normal distribution. One-
way analysis of variance (ANOVA) was conducted to determine 
whether there were any differences in Phe, Tyr, Kyn, Trp, Phe:Tyr, 
and Kyn:Trp levels between current smokers, past smokers, and 
non-smokers, and Tukey’s post hoc test was used after detecting 
significant differences. To assess smoking as a trait, current and 
past smokers were combined into a single group and compared 
with non-smokers. Logistic regression models were built to 
estimate associations between smoking status (smoker vs. non-
smoker) as dependent variable and as independent variables, in 
succession: (a) Tyr, Phe, and their ratio and (b) Kyn, Trp, and 
their ratio, with age, sex, BMI, and CPZ equivalent as covariates. 
We also used linear regressions to estimate associations between 
PANNS symptoms scores and Tyr, Phe, and their ratio and Kyn, 
Trp, and their ratio with successive adjustment for the above 
listed covariates.
resUlTs
sample Demographic and clinical 
characteristics
Age differed among the three groups of patients with current 
smokers on average being younger than past smokers (p < 0.001) 
and non-smokers as a group (Table  1). Current smokers had 
statistically higher scores on the PANSS-positive symptoms sub-
scale (p = 0.004). There was a significant difference between the 
three groups with regards to PANSS-positive symptoms subscale 
score after controlling for age, gender, and BMI [F(2,886) = 5.75, 
p =  0.003]. On post  hoc analysis, current smokers had higher 
PANSS-positive subscale scores when compared with non-
smokers (p = 0.007). The difference in positive symptoms sub-
scale between current smokers and past smokers was trending 
toward significance (p = 0.06). Data on smoking status and Phe/
Tyr and Kyn/Trp levels were available for 844 and 796 patients, 
respectively.
smoking status and Phe, Tyr,  
and Phe:Tyr ratio
There was a significant difference in Tyr levels between the 
three groups (current smoker, past smoker, and non-smoker) 
[F(2,841) = 6.48, p = 0.001] on crude analysis with current smok-
ers having lower and non-smokers having higher Tyr levels. 
The effect persisted after controlling for age, sex, BMI, and CPZ 
equivalent dosage [F(2,789) = 3.77, p = 0.02] (Table 2). There were 
no differences among the three groups in Phe levels [F(2,789) = 0.76, 
p = 0.47] and Phe:Tyr ratio [F(2,789) = 1.34, p = 0.26]. On post hoc 
pairwise analysis of the difference between the three groups in 
Tyr levels, current smokers had lower Tyr levels when compared 
with non-smokers (p = 0.006) and past smokers (p = 0.02), but 
there was no difference between past smokers and non-smokers 
(p = 0.99). This difference persisted after controlling for age, sex, 
BMI, and PANSS-positive symptoms between current smokers 
and non-smokers (p = 0.02) and was marginally trending toward 
significance for difference between current smokers and past 
smokers (p = 0.05).
Smoking as a trait was assessed by consolidating current and 
past smokers into one group (n = 605) and comparing them to 
non-smokers (n = 213) after including age, sex, BMI, and PANSS-
positive symptoms subscale scores in a logistic regression model. 
In this multivariate model, smoking (current smoking and past 
smoking) was associated with lower Tyr levels when compared 
with non-smoking (OR =  2.37, CI =  1.107–5.090, p =  0.03). 
After further including CPZ equivalent dosage in the model, the 
relationship was trending toward significance (p = 0.06). There 
was no significant association with Phe:Tyr ratio (p =  0.06) or 
Phe (p = 0.70) levels.
smoking status and Trp, Kyn,  
and Kyn:Trp ratio
There were statistically significant differences in Kyn levels 
among the three groups (current smoker, past smoker, and non-
smoker) after adjusting for age, sex, BMI, and CPZ equivalent 
[F(2,738) =  3.165, p =  0.04] that did not resist adjustment with 
PANSS-positive symptoms additionally but was trending toward 
significance [F(2,738)  =  2.81, p  =  0.06] (Table  2). On post  hoc 
pairwise analysis, current smokers had lower Kyn levels when 
compared with past smokers (p =  0.04) but after adjusting for 
PANSS-positive symptoms, this difference was trending toward 
significance (p  =  0.05). There were no differences between 
TaBle 2 | Means and sDs of monoamine precursors/metabolites and differences among the three groups after log transforming levels and adjusting 
for age, sex, BMi, and cPZ equivalent.
Precursor/metabolite (units) current smoker mean ± sD (n) Past smoker mean ± sD (n) never smoker mean ± sD (n) anOVa F ratio/p-Value
Phe (μmol/L) 75.11 ± 36.02 (506) 80.715 ± 37.64 (119) 76.53 ± 33.45 (219) 0.75/0.47
Tyr (μmol/L) 74.185 ± 32.89 (506) 86.68 ± 50.19 (119) 82.71 ± 35.92 (219) 3.77/0.02
Phe:Tyr 1.14 ± 0.64 (506) 1.08 ± 0.54 (119) 1.06 ± 0.66 (219) 1.33/0.26
Kyn (μmol/L) 2.60 ± 1.47 (470) 3.07 ± 1.85 (113) 2.81 ± 1.63 (213) 3.17/0.04
Trp (μmol/L) 65.40 ± 52.82 (470) 63.97 ± 42.21 (113) 61.30 ± 16.52 (213) 0.41/0.66
Kyn:Trp 44.44 ± 26.96 (470) 54.92 ± 39.86 (113) 48.94 ± 36.64 (213) 4.07/0.02
Phe, phenylalanine; Tyr, tyrosine; Phe:Tyr, phenylalanine:tyrosine; Kyn, kynurenine; Trp, tryptophan; Kyn:Trp, kynurenine:tryptophan; Phe:Tyr, phenylalanine:tyrosine. Bold font 
numerals denote statistically significant results.
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current smokers and non-smokers (p = 0.4) or past smokers and 
non-smokers (p = 0.4).
Kyn:Trp ratio differed among the three groups after adjusting 
for age, sex, BMI, CPZ equivalent, and PANSS-positive symptoms 
[F(2,738) = 3.61, p = 0.03]. On post hoc analysis, current smokers 
had higher Kyn:Trp ratio (p = 0.02) when compared with past 
smokers, but there were no differences between current smokers 
and non-smokers (p = 0.50) or past smokers and non-smokers 
(p = 0.30). There were no differences among the three groups in 
terms of Trp levels [F(2,738) = 0.412, p = 0.66].
Comparison of smoking (after consolidating current smok-
ers and past smokers into one group) to non-smoking did not 
reveal any differences with regards to Kyn (p = 0.50), Trp levels 
(p = 0.60), or Kyn:Trp ratio (p = 0.70).
symptom severity and Phe, Tyr, 
and Phe:Tyr ratio
Positive and negative syndrome scale general psychopathology 
subscale scores negatively correlated with Phe:Tyr ratio (n = 837, 
coefficient = −4.3, p = 0.01) after controlling for age, sex, and BMI 
but did not show any significant correlation with Phe (p = 0.07), 
Tyr (p = 0.4), Kyn (p = 0.90), Trp (p = 0.90), or Kyn:Trp ratio 
(p = 0.80).
DiscUssiOn
In the first study of its kind, we provide evidence that, among 
patients with a diagnosis of schizophrenia, smoking is associated 
with a decrease in Tyr levels. We had previously reported that 
plasma Phe levels and Phe:Tyr ratio were elevated in schizo-
phrenia patients when compared with normal controls with no 
difference in continuous Tyr levels. However, having a diagnosis 
of schizophrenia was associated with Tyr levels in the lowest 25th 
percentile when compared with healthy controls (40). Our study 
suggests further differences in Tyr levels within this sample of 
patients based on their smoking status. As a limitation, we did 
not have data on smoking status in healthy controls that were 
included for the parent study and, as such, they could not be used 
in the current analysis.
Previous work affirmed that smoking induces a Th1 to Th2 
shift in immune activation (46). This is consistent with our finding 
of decreased Kyn levels in current smokers, further aligned with 
previous reports on decreases in Th1 immunity with reduction in 
activity of IDO (32). However, Tyr levels decreased, rather than 
increased, with smoking. This effect may be mediated, independ-
ent of inflammation, by nicotine’s ability to increase TH gene 
expression, both centrally and peripherally, thus contributing to 
the decreased level of Tyr (34, 36, 47).
Finding an elevated Kyn:Trp ratio in current smokers relative 
to past smokers in our study is not consistent with previously 
described decreased Kyn:Trp ratio in smokers, which was 
explained as a consequence of decreased activity of IDO as a result 
of a putative smoking-induced Th1 to Th2 shift (32). Additionally, 
finding a high Kyn:Trp ratio and low, rather than high Kyn levels, 
seems difficult to explain. Nevertheless, this is possible in the event 
of non-significant decreases in Trp levels due to decreased dietary 
intake (broadly reported in smokers), increased utilization via 
Trp 2,3-dioxygenase (TDO) pathway [potentially as a result of 
hypothalamic–pituitary–adrenal (HPA) axis activation as a result 
of increased vulnerability to stress] or increased availability of 
vitamin cofactors involved in Kyn metabolism (48).
Because decreased Tyr levels (even after adjustment for demo-
graphic variables, BMI, and symptoms scores and reduced to a low 
grade statistical trend after adjustment for CPZ equivalent) were 
found in smokers (current and past smokers), it is possible that 
decreased Tyr levels could be a trait marker for smoking or even 
contribute to vulnerability for smoking. Patients with schizophre-
nia have a higher prevalence of smoking when compared with 
patients with other major mental illnesses (49). The increased 
prevalence of smoking may not, as some believe, be a consequence 
of psychosis or progression of the illness, or attempts to achieve 
symptomatic control, as high rates of smoking in patients with 
schizophrenia were documented even before their first psychotic 
episode (50) with the caveat of not excluding the possibility of a 
link between smoking and prodromal symptoms of the illness. 
As low Tyr levels are associated with schizophrenia (51), it might 
be possible that reduced Tyr levels, susceptibility for smoking, 
and schizophrenia are linked by upstream molecular factors, such 
as genetic or epigenetic factors. Studies linking allelic variation 
in the TH gene and susceptibility to smoking lends additional 
credence to this hypothesis (38, 39) within the general context 
of elevated rates of smoking in first-degree relatives of patients 
with schizophrenia (52) and higher rates of smoking in twins 
discordant for the illness (53).
The cross-sectional design of the study is one of the major 
limitations of this study as it leads to an inability to estimate a 
direction of causality. Measurement of inflammatory markers like 
cytokines and C-reactive protein (CRP) would have been useful 
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to additionally assess immune links (e.g., Th1 vs. Th2) but una-
vailability of sufficient amounts of plasma to assay these markers 
was prohibitive. We depended on patient reports to determine 
smoking status as opposed to more objective measures of smok-
ing like serum concentrations of cotinine or carbon monoxide in 
expired air.
Considering elements of feasibility for achieving the main aims 
of the parent project, fasting protocols were not observed prior to 
obtaining blood for determination of plasma amino acid levels, 
possibly resulting in increased heterogeneity and lower power to 
uncover significant associations, but there is no reason to believe 
that a systematic bias spuriously led to our positive results. Food 
preferences and timing of meals are potential sources of bias as 
proximity to meals and dietary preference can significantly affect 
plasma Tyr levels (54). Moreover, smoking has a suppressive 
effect on appetite, which may independently have interactions 
with levels of plasma amino acids (55). Furthermore, there are 
diurnal variations in plasma amino acid levels that have not been 
taken into account (54). Importantly, plasma levels of amino acids 
may not accurately represent central availability. We were unable 
to obtain cerebrospinal fluid (CSF) samples to ascertain amino 
acid levels, and we do believe that the CSF findings, although 
theoretically more illuminating, would have little practical value. 
We have not accounted for the duration of illness, number of past 
active episodes, or clinical status at the time of study.
We did not have systematic information on potential nicotine 
supplementation, particularly in past smokers, and, previously, 
sustained elevations of TH activity after nicotine administration 
(37) have been documented. We also have not accounted for 
menstrual status and menstrual cycle phase, which might alter 
smoking habits and relapses after abstinence (56, 57).
Despite these limitations, the study has several strengths 
including a large sample size and a relatively homogenous sam-
ple of patients with schizophrenia as confirmed by SCID, while 
excluding other psychosis-spectrum diagnoses like schizoaffec-
tive disorder and schizophreniform disorder.
A growing trend in clinical neuroscience is to affirm that 
only brain (and CSF) biochemistry is truly relevant to psycho-
pathology, i.e., peripheral molecules in the blood are of little 
relevance for advancing our understanding of mental illness 
and its manifestations. While, of course, we do not dispute the 
paramount importance of chemical processes within the brain, 
we strongly believe that discarding the relevance of blood levels 
is counterproductive, especially when we refer to precursors 
of neurotransmitters that can be easily measured in most of 
the patients. Moreover, levels of certain molecules in blood are 
predictively associated not only with the metabolism of the brain 
but also with its functional anatomy. In support of our opinion, 
several of us have coauthored a recent article reporting that 
molecules of the Kyn pathway are associated with white mat-
ter biochemistry and microstructure (58). Specifically, fasting 
Kyn:Trp ratio, which was higher in patients with schizophrenia 
than controls, positively correlated with frontal white matter 
glutamate levels in both groups. Moreover, in patients, but not in 
controls, plasma Trp levels correlated negatively with diffusion 
tensor imaging (DTI) fractional anisotropy (FI), a measure of 
white matter integrity (58).
Studies with improved methodologies like objective measures 
of smoking, longitudinal designs, and interventional approaches 
can elucidate the role that low Tyr plays in relationship to smok-
ing in schizophrenia and if there is any potential of uncovering 
new targets for pharmacological interventions. These efforts are 
well justified considering the staggering rates of smoking and 
increased cardiovascular mortality in schizophrenia patients.
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